Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2026)

Arcus Biosciences' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $209.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 8.85% year-over-year to $209.0 million; the TTM figure through Mar 2026 stood at $209.0 million (up 8.85% YoY), while the FY2025 annual figure was $231.0 million, up 2.21% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $209.0 million, down from $231.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $235.0 million in Q3 2025, with the low at $4.0 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $199.0 million (2024), against an average of $187.3 million.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities plunged 97.52% in 2023, then surged 5000.0% in 2024.
• Arcus Biosciences' Total Current Liabilities stood at $193.0 million in 2022, then declined by 4.66% to $184.0 million in 2023, then grew by 22.83% to $226.0 million in 2024, then rose by 2.21% to $231.0 million in 2025, then fell by 9.52% to $209.0 million in 2026.
• Business Quant data shows RCUS's Total Current Liabilities at $209.0 million in Q1 2026, $231.0 million in Q4 2025, and $235.0 million in Q3 2025.